Ectopic expression miR-17-92 in CAR-T cells confers improved protection following tumor re-challenge. (A) Schematic of the experimental protocol. CAR-T-cell-treated mice that survived at least for 35 days in the experiment shown in Figure 4 [4 mice receiving 3C10-T-cells without miR and 3 mice treated with T-cells co-transduced with 3C10 plus miR-17-92] received i.c. re-challenge with U87-EGFRvIII-Luc cells (5×105/mice) on day 49. No additional CAR T-cells were injected. (B) Longitudinal measurements of tumor-derived mean photon flux ± SD from the 2 groups of mice. The background luminescence level (up to 103 p/s) was defined based on the levels observed in non-tumor-bearing mice imaged in parallel with tumor-bearing mice in treatment groups. *p < 0.05 by Wilcoxon rank-sum test.